APA (7th ed.) Citation

Chan, S. L., Schuler, M., Kang, Y., Yen, C., Edeline, J., Choo, S. P., . . . Lim, H. Y. (2022). A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental & Clinical Cancer Research (17569966), 41(1), 1. https://doi.org/10.1186/s13046-022-02383-5

Chicago Style (17th ed.) Citation

Chan, Stephen L., et al. "A First-in-human Phase 1/2 Study of FGF401 and Combination of FGF401 with Spartalizumab in Patients with Hepatocellular Carcinoma or Biomarker-selected Solid Tumors." Journal of Experimental & Clinical Cancer Research (17569966) 41, no. 1 (2022): 1. https://doi.org/10.1186/s13046-022-02383-5.

MLA (9th ed.) Citation

Chan, Stephen L., et al. "A First-in-human Phase 1/2 Study of FGF401 and Combination of FGF401 with Spartalizumab in Patients with Hepatocellular Carcinoma or Biomarker-selected Solid Tumors." Journal of Experimental & Clinical Cancer Research (17569966), vol. 41, no. 1, 2022, p. 1, https://doi.org/10.1186/s13046-022-02383-5.